# An Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic Alzheimer's Disease

> **NCT07724132** · PHASE3 · RECRUITING · sponsor: **University College, London** · enrollment: 1200 (estimated)

## Conditions studied

- Alzheimer's Disease (AD)
- Mild Cognitive Impairment Due to Alzheimer's Disease
- Alzheimer Disease Dementia

## Interventions

- **DRUG:** Placebo
- **DRUG:** Atomoxetine
- **DRUG:** Metformin 1000 mg Oral Tablet

## Key facts

- **NCT ID:** NCT07724132
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-24
- **Primary completion:** 2031-03
- **Final completion:** 2031-03
- **Target enrollment:** 1200 (ESTIMATED)
- **Last updated:** 2026-07-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07724132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07724132, "An Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic Alzheimer's Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07724132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*